STOCK TITAN

[Form 4] Fortrea Holdings Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Mark A. Morais, Chief Operating Officer of Fortrea Holdings Inc. (FTRE), reported settlement and related sales tied to time-vesting RSUs converted from Labcorp. On 08/18/2025, 11,312 Restricted Stock Units (RSUs) settled into Common Stock at $0 per share as scheduled following the Labcorp spin-off; those RSUs vested on 08/17/2025. On 08/19/2025 the reporting person sold 4,886 shares in a "sell to cover" required to satisfy tax withholding, executed in multiple trades at prices ranging from $7.89 to $8.10 with a weighted average of $8.01. Following these transactions the reporting person beneficially owned 52,975 shares directly and reported an indirect interest in 4,625 shares owned by a spouse, which were inadvertently omitted from prior filings.

Mark A. Morais, Chief Operating Officer di Fortrea Holdings Inc. (FTRE), ha comunicato la liquidazione e relative vendite connesse a RSU a maturazione temporale convertite da Labcorp. Il 18/08/2025 si sono liquidate 11.312 Restricted Stock Units (RSU) trasformate in azioni ordinarie a $0 per azione, come previsto dopo lo spin-off da Labcorp; tali RSU sono vestite il 17/08/2025. Il 19/08/2025 il soggetto segnalante ha venduto 4.886 azioni in un'operazione di "sell to cover" per soddisfare le ritenute fiscali, eseguita in più operazioni a prezzi compresi tra $7,89 e $8,10, con prezzo medio ponderato di $8,01. A seguito di queste operazioni, il segnalante deteneva direttamente 52.975 azioni e ha dichiarato un interesse indiretto in 4.625 azioni possedute dal coniuge, precedentemente omesse per errore dalle dichiarazioni.

Mark A. Morais, Chief Operating Officer de Fortrea Holdings Inc. (FTRE), informó la liquidación y ventas relacionadas con RSU de adquisición temporal convertidas desde Labcorp. El 18/08/2025 se liquidaron 11.312 Restricted Stock Units (RSU) que se convirtieron en acciones ordinarias a $0 por acción según lo programado tras la escisión de Labcorp; dichas RSU vencieron el 17/08/2025. El 19/08/2025 la persona informante vendió 4.886 acciones en una operación de "sell to cover" para cubrir retenciones fiscales, ejecutada en múltiples transacciones a precios entre $7,89 y $8,10, con un precio medio ponderado de $8,01. Tras estas operaciones, la persona informante poseía de forma directa 52.975 acciones e informó un interés indirecto en 4.625 acciones pertenecientes a su cónyuge, que se omitieron por error en presentaciones anteriores.

Fortrea Holdings Inc.(FTRE) 최고운영책임자(COO) Mark A. Morais는 Labcorp에서 전환된 시간 기반 RSU의 정산 및 관련 매각을 보고했습니다. 2025년 8월 18일에 11,312개의 제한주식단위(Restricted Stock Units, RSU)가 Labcorp 분사에 따라 예정대로 주당 $0로 보통주로 정산되었고, 해당 RSU는 2025년 8월 17일에 취득(vesting)되었습니다. 2025년 8월 19일 보고자는 세금 원천징수를 충당하기 위한 "sell to cover" 방식으로 4,886주를 여러 거래로 매도했으며, 거래 가격은 $7.89에서 $8.10 사이, 가중평균 가격은 $8.01이었습니다. 이들 거래 이후 보고자는 직접적으로 52,975주를 보유하고 있으며, 이전 제출서류에서 누락된 배우자 소유 4,625주에 대한 간접적 이익을 신고했습니다.

Mark A. Morais, Chief Operating Officer de Fortrea Holdings Inc. (FTRE), a déclaré le règlement et les ventes liées à des RSU à acquisition temporelle converties depuis Labcorp. Le 18/08/2025, 11 312 Restricted Stock Units (RSU) ont été réglées en actions ordinaires à 0 $ par action, comme prévu suite au spin-off de Labcorp ; ces RSU ont acquis leurs droits le 17/08/2025. Le 19/08/2025, la personne déclarant a vendu 4 886 actions dans le cadre d'une opération de "sell to cover" pour satisfaire les retenues fiscales, exécutée en plusieurs transactions à des prix allant de 7,89 $ à 8,10 $, avec une moyenne pondérée de 8,01 $. À la suite de ces opérations, la personne déclarant détenait directement 52 975 actions et a signalé un intérêt indirect sur 4 625 actions détenues par son conjoint, omises par erreur dans les déclarations antérieures.

Mark A. Morais, Chief Operating Officer von Fortrea Holdings Inc. (FTRE), meldete die Abwicklung und damit verbundene Verkäufe im Zusammenhang mit zeitabhängigen RSUs, die von Labcorp umgewandelt wurden. Am 18.08.2025 wurden 11.312 Restricted Stock Units (RSUs) planmäßig in Stammaktien zu $0 pro Aktie abgerechnet; diese RSUs sind am 17.08.2025 vestet. Am 19.08.2025 verkaufte die meldende Person 4.886 Aktien in einer "sell to cover"-Transaktion zur Begleichung der Steuerabzüge, ausgeführt in mehreren Trades zu Preisen zwischen $7,89 und $8,10 mit einem gewichteten Durchschnittspreis von $8,01. Nach diesen Transaktionen hielt die meldende Person direkt 52.975 Aktien und meldete ein indirektes Interesse an 4.625 Aktien, die vom Ehepartner gehalten werden und zuvor irrtümlich in früheren Meldungen ausgelassen wurden.

Positive
  • Settlement of 11,312 RSUs into common stock as scheduled, reflecting compensation vesting converted from Labcorp RSUs
  • Sell-to-cover transactions were plan-mandated to satisfy tax withholding rather than discretionary sales
  • Correction disclosed for previously omitted indirect ownership of 4,625 shares owned by spouse
Negative
  • Prior omission of spouse-owned 4,625 shares in earlier filings, indicating a disclosure lapse that required correction

Insights

TL;DR: Routine RSU vesting and mandated sell-to-cover tax sale; modest net increase in beneficial holdings after settlement.

The report documents non-discretionary equity events: conversion and vesting of 11,312 RSUs into common shares and a contemporaneous sell-to-cover of 4,886 shares to satisfy tax withholding at a weighted average price of $8.01. These are compensation-related transactions, not open-market investment decisions, and they modestly change disclosed share counts. No cash proceeds or other corporate actions beyond the Labcorp-to-Fortrea RSU conversion are indicated.

TL;DR: Disclosure is standard but includes a corrected omission of spouse-owned shares that should improve record accuracy.

The Form 4 properly discloses settlement, a required sell-to-cover, and corrects an inadvertent omission of 4,625 shares held by the reporting person’s spouse. While the correction is remedial and improves compliance with Section 16 reporting, the omission highlights the importance of thorough pre-filing review for insider holdings. Transactions were executed pursuant to plan-mandated terms, not discretionary trades.

Mark A. Morais, Chief Operating Officer di Fortrea Holdings Inc. (FTRE), ha comunicato la liquidazione e relative vendite connesse a RSU a maturazione temporale convertite da Labcorp. Il 18/08/2025 si sono liquidate 11.312 Restricted Stock Units (RSU) trasformate in azioni ordinarie a $0 per azione, come previsto dopo lo spin-off da Labcorp; tali RSU sono vestite il 17/08/2025. Il 19/08/2025 il soggetto segnalante ha venduto 4.886 azioni in un'operazione di "sell to cover" per soddisfare le ritenute fiscali, eseguita in più operazioni a prezzi compresi tra $7,89 e $8,10, con prezzo medio ponderato di $8,01. A seguito di queste operazioni, il segnalante deteneva direttamente 52.975 azioni e ha dichiarato un interesse indiretto in 4.625 azioni possedute dal coniuge, precedentemente omesse per errore dalle dichiarazioni.

Mark A. Morais, Chief Operating Officer de Fortrea Holdings Inc. (FTRE), informó la liquidación y ventas relacionadas con RSU de adquisición temporal convertidas desde Labcorp. El 18/08/2025 se liquidaron 11.312 Restricted Stock Units (RSU) que se convirtieron en acciones ordinarias a $0 por acción según lo programado tras la escisión de Labcorp; dichas RSU vencieron el 17/08/2025. El 19/08/2025 la persona informante vendió 4.886 acciones en una operación de "sell to cover" para cubrir retenciones fiscales, ejecutada en múltiples transacciones a precios entre $7,89 y $8,10, con un precio medio ponderado de $8,01. Tras estas operaciones, la persona informante poseía de forma directa 52.975 acciones e informó un interés indirecto en 4.625 acciones pertenecientes a su cónyuge, que se omitieron por error en presentaciones anteriores.

Fortrea Holdings Inc.(FTRE) 최고운영책임자(COO) Mark A. Morais는 Labcorp에서 전환된 시간 기반 RSU의 정산 및 관련 매각을 보고했습니다. 2025년 8월 18일에 11,312개의 제한주식단위(Restricted Stock Units, RSU)가 Labcorp 분사에 따라 예정대로 주당 $0로 보통주로 정산되었고, 해당 RSU는 2025년 8월 17일에 취득(vesting)되었습니다. 2025년 8월 19일 보고자는 세금 원천징수를 충당하기 위한 "sell to cover" 방식으로 4,886주를 여러 거래로 매도했으며, 거래 가격은 $7.89에서 $8.10 사이, 가중평균 가격은 $8.01이었습니다. 이들 거래 이후 보고자는 직접적으로 52,975주를 보유하고 있으며, 이전 제출서류에서 누락된 배우자 소유 4,625주에 대한 간접적 이익을 신고했습니다.

Mark A. Morais, Chief Operating Officer de Fortrea Holdings Inc. (FTRE), a déclaré le règlement et les ventes liées à des RSU à acquisition temporelle converties depuis Labcorp. Le 18/08/2025, 11 312 Restricted Stock Units (RSU) ont été réglées en actions ordinaires à 0 $ par action, comme prévu suite au spin-off de Labcorp ; ces RSU ont acquis leurs droits le 17/08/2025. Le 19/08/2025, la personne déclarant a vendu 4 886 actions dans le cadre d'une opération de "sell to cover" pour satisfaire les retenues fiscales, exécutée en plusieurs transactions à des prix allant de 7,89 $ à 8,10 $, avec une moyenne pondérée de 8,01 $. À la suite de ces opérations, la personne déclarant détenait directement 52 975 actions et a signalé un intérêt indirect sur 4 625 actions détenues par son conjoint, omises par erreur dans les déclarations antérieures.

Mark A. Morais, Chief Operating Officer von Fortrea Holdings Inc. (FTRE), meldete die Abwicklung und damit verbundene Verkäufe im Zusammenhang mit zeitabhängigen RSUs, die von Labcorp umgewandelt wurden. Am 18.08.2025 wurden 11.312 Restricted Stock Units (RSUs) planmäßig in Stammaktien zu $0 pro Aktie abgerechnet; diese RSUs sind am 17.08.2025 vestet. Am 19.08.2025 verkaufte die meldende Person 4.886 Aktien in einer "sell to cover"-Transaktion zur Begleichung der Steuerabzüge, ausgeführt in mehreren Trades zu Preisen zwischen $7,89 und $8,10 mit einem gewichteten Durchschnittspreis von $8,01. Nach diesen Transaktionen hielt die meldende Person direkt 52.975 Aktien und meldete ein indirektes Interesse an 4.625 Aktien, die vom Ehepartner gehalten werden und zuvor irrtümlich in früheren Meldungen ausgelassen wurden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Morais Mark A.

(Last) (First) (Middle)
8 MOORE DRIVE

(Street)
DURHAM NC 27709

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fortrea Holdings Inc. [ FTRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Operating Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/18/2025 M 11,312 A $0(1) 57,861 D
Common Stock(2) 08/19/2025 S 4,886 D $8.01(3) 52,975(4) D
Common Stock 4,625(5) I Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 08/18/2025 M 11,312 (6) (6) Common Stock 11,312 $0 88,632(7) D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents the right to receive, at settlement, one share of Fortrea Holdings Inc. ("Fortrea") Common Stock. This transaction represents the settlement of RSUs into Common Stock on their scheduled vesting date.
2. The sales reported on this Form 4 represent shares of Common Stock sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
3. This transaction was executed in multiple trades at prices ranging from $7.89 to $8.10. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. This number reflects the aggregate amount of Common Stock held by the reporting person.
5. The balance reflects an indirect interest in 4,625 shares owned by the spouse of the reporting person, whom the reporting person recently married, which were inadvertently omitted from prior filings.
6. In connection with the spin-off of Fortrea by Laboratory Corporation of America Holdings ("Labcorp"), RSUs granted by Labcorp were converted into time-vesting RSUs of Fortrea pursuant to the terms of the Employee Matters Agreement. These RSUs vested on August 17, 2025.
7. This number reflects the aggregate number of RSUs held by the reporting person.
/s/ James Stillman Hanson, Attorney-in-Fact for Mark A. Morais 08/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What RSU activity did FTRE insider Mark A. Morais report?

The reporting person had 11,312 RSUs settle into common stock on 08/18/2025 following vesting converted from Labcorp RSUs.

Why were shares sold by the reporting person on 08/19/2025?

The sales of 4,886 shares were "sell to cover" transactions mandated to satisfy tax withholding obligations associated with RSU vesting.

At what prices were the shares sold and what was the weighted average?

Sales were executed in multiple trades at prices ranging from $7.89 to $8.10; the reported weighted average price was $8.01.

How many shares does Mark A. Morais beneficially own after these transactions?

The Form 4 reports 52,975 shares held directly following the transactions and an indirect interest in 4,625 shares owned by a spouse.

Was there any correction or restatement in this filing?

Yes. The filing discloses an inadvertent omission of 4,625 spouse-owned shares from prior filings and corrects the record.
Fortrea Holdings

NASDAQ:FTRE

FTRE Rankings

FTRE Latest News

FTRE Latest SEC Filings

FTRE Stock Data

701.88M
90.37M
0.46%
111.13%
14.26%
Biotechnology
Services-medical Laboratories
Link
United States
DURHAM